The CheckMate‐143 (NCT02017717) phase I clinical trial evaluates the effectiveness and safety of nivolumab (PD‐1 inhibitor) alone or in combination with ipilimumab (CTLA‐4 inhibitor) in recurrent GBM. This evidence concerns the gene PDCD1 and glioblastoma.